Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Símbolo de cotizaciónELUT
Nombre de la empresaElutia Inc
Fecha de salida a bolsaOct 08, 2020
Director ejecutivoMills (C. Randal)
Número de empleados51
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 08
Dirección12510 Prosperity Drive
CiudadSILVER SPRING
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20904
Teléfono12402471143
Sitio Webhttps://elutia.com/
Símbolo de cotizaciónELUT
Fecha de salida a bolsaOct 08, 2020
Director ejecutivoMills (C. Randal)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos